1228553-77-2 Usage
General Description
(S)-8-tert-butylchroman-4-amine, also known as ABT-239, is a chemical compound that belongs to the class of chroman-4-amine derivatives. It is a potent and selective inhibitor of the histamine H3 receptor, which is involved in the regulation of histamine release and neurotransmitter synthesis. ABT-239 has shown promising potential as a therapeutic agent for various central nervous system disorders, including cognitive impairment, attention-deficit hyperactivity disorder, and schizophrenia. Its unique chemical structure and pharmacological properties make it a valuable tool for studying the role of the histamine H3 receptor in neurobiology and for developing new treatments for neurological disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 1228553-77-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,8,5,5 and 3 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1228553-77:
(9*1)+(8*2)+(7*2)+(6*8)+(5*5)+(4*5)+(3*3)+(2*7)+(1*7)=162
162 % 10 = 2
So 1228553-77-2 is a valid CAS Registry Number.
1228553-77-2Relevant articles and documents
Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists
Schmidt, Robert G.,Bayburt, Erol K.,Latshaw, Steven P.,Koenig, John R.,Daanen, Jerome F.,McDonald, Heath A.,Bianchi, Bruce R.,Zhong, Chengmin,Joshi, Shailen,Honore, Prisca,Marsh, Kennan C.,Lee, Chih-Hung,Faltynek, Connie R.,Gomtsyan, Arthur
, p. 1338 - 1341 (2011/04/23)
Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.
